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Background. Models of cancer-induced neuropathy are designed by injecting cancer cells near the peripheral nerves. The
interference of tissue-resident immune cells does not allow a direct contact with nerve fibres which affects the tumor mi-
croenvironment and the invasion process. Methods. Anaplastic tumor-1 (AT-1) cells were inoculated within the sciatic nerves
(SNs) of male Copenhagen rats. Lumbar dorsal root ganglia (DRGs) and the SNs were collected on days 3, 7, 14, and 21. SN
tissues were examined for morphological changes and DRG tissues for immunofluorescence, electrophoretic tendency, and
mRNA quantification. Hypersensitivities to cold, mechanical, and thermal stimuli were determined. HC-030031, a selective
TRPA1 antagonist, was used to treat cold allodynia. Results. Nociception thresholds were identified on day 6. Immunoflu-
orescent micrographs showed overexpression of TRPA1 on days 7 and 14 and of CGRP on day 14 until day 21. Both TRPA1 and
CGRP were coexpressed on the same cells. Immunoblots exhibited an increase in TRPA1 expression on day 14. TRPA1 mRNA
underwent an increase on day 7 (normalized to 18S). Injection of HC-030031 transiently reversed the cold allodynia.
Conclusion. A novel and a promising model of cancer-induced neuropathy was established, and the role of TRPA1 and CGRP
in pain transduction was examined.
1. Introduction
Tumors spread through vascular, lymphatic, and/or neural
routes. The latter is characteristic in cases of head and
neck, pancreas, colon, rectum, prostate, biliary tract, and
stomach cancers [1]. In these cases, 30% to 50% of patients
suffer from moderate to severe pain [2]. The neuronal
invasion varies from type to type. In pancreatic cancer, for
example, the frequency is 90% or 100% [3]. The first model
of neuropathic pain was developed in 1979 as a peripheral
nerve injury [4]. Two years later, the chronic constriction
injury “CCI” [5], which is still one of the most popular
models for studying neuropathic pain in peripheral nerves,
was developed.
Previously, cancer-induced neuropathy was modeled
by injecting cancer cells in the proximity of the sciatic nerve
(SN) [6, 7], promoting such models to study the invasion of
malignant cells. However, the resident immune cells lo-
cated in the surrounding tissue, such as the gluteal region,
may interfere with evaluation of invasiveness and in-
vestigation of molecular mechanisms within the tumor
microenvironment. To overcome the interference of these
tissue-resident immune cells, which affects the onset of
cancer pain and the regulation of the proteins involved in
the invasion process, we introduce a novel cancer-induced
neuropathic pain model. In this model, we directly in-
oculated the tumor cells within the neuronal sheath, which
allowed a direct contact with the neuronal fibers from the
time of injection.
To establish this model, we injected prostatic
adenocarcinoma-derived cancer cells in the SN of
Copenhagen rats. The cancer cells proliferated and gen-
erated spontaneous pain behavior and hypersensitivity,
which later caused neuronal damage. We evaluated the
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tumor growth and measured the induced cold allodynia
and mechanical and thermal hyperalgesia as indicators of
pain development. Tissues were collected from the dorsal
root ganglia (DRGs) to quantify the pain-recognition re-
ceptor, TRPA1, in parallel with the marker of tumor
progress and the pain transducer, CGRP, and to study the
underlying molecular mechanisms.
Transient receptor potential ankyrin 1 (TRPA1) plays
a role in cold, mechanical, and thermal pain recognition. It is
produced in a wide variety of tissues such as those in the
central (CNS) [8] and peripheral (PNS) [9–12] nervous
systems, eye [13], lung [14], gastrointestinal tract [15], genital
systems [16], skin [17], cardiovascular system [18], urinary
system [9, 10], and teeth [19, 20]. In some inflammatory
conditions, such as streptozotocin-induced type I diabetes in
rats [9] and cyclophosphamide-induced cystitis and hyper-
algesia inmice bladders [10], TRPA1 is overexpressed byDRG
neurons. In these tissues, the activation and the regulatory
mechanisms of TRPA1 through local inflammation have been
extensively investigated. However, TRPA1 regulation in
cancer-induced peripheral neuropathy has not yet been
studied.
Calcitonin gene-related peptide (CGRP), a 37-residue
neuropeptide produced in sensory, motor, and autonomic
neurons, is a potent vasodilator [21]. Vasodilation enhances
the progression of cancer mainly through angiogenesis and
lymph angiogenesis [22]. CGRP plays another role in
transmitting signals of somatic, visceral, and neuropathic
pain [23, 24]. Its production is correlated to the expression of
TRPA1 in several inflammatory diseases such as colonic
distension [25], carrageenan-induced chronic prostatitis and
pelvic pain syndrome [26], and lipopolysaccharide-induced
inflammation [27].
To confirm the nociceptive role of TRPA1 in our model
of cold allodynia, we used HC-030031 to antagonize the
TRPA1 channel. HC-030031 has a high selectivity for
the TRPA1 receptor and is used for treating hyperalgesia
in cyclophosphamide-produced [10], prostaglandin E2-
produced [11], and carrageenan-produced [12] pain models.
2. Methods
In our model, we used inbredmale Copenhagen rats (Project
Code: G 0314/13) for their major histocompatibility complex
haplotype RT1av1. This allows 100% growth of the trans-
plantable tumor cells as previously reported [28]. These
tumor cells, anaplastic tumor-1 (AT-1), were derived from
the Dunning R3327 cell line and characterized by being
androgen independent, nonmetastasizing, and having a very
rapid growth rate [29]. The parental Dunning R3327 itself
was derived from male Copenhagen rats (cf. thymic tumor
which is more common in females) [30] and discovered as
a spontaneous tumor in a 22-month-old male Copenhagen
rat. It was first observed at a necropsy from the 54th
brother× sister generation of its preceding cell line 2331
[31–33].
The study was approved by the State Office for Health
and Social Affairs (LAGeSo, Berlin, Germany) and in
adherence to the guidelines and the standards of Charite´–
University of Medicine Berlin.
2.1. Copenhagen Rats (COP/CrCrl). Rats were obtained,
through the Research Institutes for Experimental Medicine
“FEM,” Charite´–University of Medicine Berlin, from
Charles River Laboratories International, Inc., Cologne,
Germany. They arrived with initial weights between 230 and
250 g and were housed at standard conditions of number per
cage, food and water supply, and light exposure. A daily
checkup was conducted to ensure normal life activities like
moving, walking, playing, lying down, rising, and jumping.
The degree of pain was scored during the whole research
period.
2.2. Tumor Cell Injection and Tissue Collection. We searched
for different cancer cell lines that are capable of developing
tumor in Copenhagen rats. Preliminary tests were per-
formed for AR42J (ECACC, Salisbury, UK; Cat. #: 93100618)
and AT-1 (ECACC; Cat. #: 94101449) cell lines.
Each rat was initially anesthetized with isoflurane
and then maintained at 2% isoflurane in O2 inhalation
throughout the operation time. The right hind leg (the ip-
silateral) was shaved and sterilized with alcohol and iodine.
To expose the SN, an incision was made in the skin between
the gluteus superficialis and the biceps femoris muscles.
The amphicrine AR42J cells were slowly inoculated
(0.5×106) in the perineurium sheath of the SN of two
successive groups of rats (n 5 each) using a 25μL
Hamilton® GASTIGHT® syringe, 1702LT Series (Sigma-
Aldrich Chemie GmbH) and watched for 40 days. Behav-
ioral tests were measured on daily basis during the first two
weeks and then every 5–7 days until the end of the obser-
vation period. We did not notice any tumor growth in SNs,
and all animals recovered from surgery.
AT-1 cells (1.0×106) were then injected in another group
of rats. During the first week, animals developed a sponta-
neous pain behavior and showed a varying degree of itching
at the injection site. After being sacrificed, AT-1 cells showed
a severe malignant growth outside the SN and in solid at-
tachment to the muscles and the inner layers of the skin.
Therefore, we reduced the number of injected AT-1 cells to
(0.5×106). The growth rate of the tumor cells decreased with
no invasion to the surrounding tissues. This number of cells
was maintained for injection throughout the consecutive
studies. Metamizole sodium was injected as a postsurgical
analgesic and added to the drinking water for 3 days after.
Tissues of lumbar L3–5 DRGs were collected and stored at
−80°C as groups of sham at 3, 7, 14, and 21 days.
The anaplastic tumor AT-1 cells were cultivated in
a medium of RPMI 1640, L-glutamine, dexamethasone, and
10% foetal bovine serum (FBS). Then, they were maintained
at 37°C and 5% CO2 atmosphere and counted under a light
microscope using the Bright-Line™ Hemacytometer slide
(Sigma-Aldrich Chemie GmbH, Steinheim, Germany). After
suspending the cells in a pH-7.4 phosphate-buffered saline
(PBS) as a vehicle, sham-operated rats were injected with
this PBS and used as a control in all consecutive assays.
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2.3. Chemicals and Equipment. Polyclonal rabbit anti-
TRPA1 and monoclonal mouse anti-CGRP antibodies
were purchased from Santa Cruz Biotechnology, Inc.,
Heidelberg, Germany (Cat. #: sc-66808), and Sigma-Aldrich
Chemie GmbH (Product #: C7113), respectively; the cor-
responding secondary antibodies, Alexa Fluor® 594 donkey
anti-rabbit IgG (Cat. #: A-21207) and Alexa Fluor 488
donkey anti-mouse IgG (Cat. #: A-21202), from Thermo
Scientific™, IL, USA; the horseradish peroxidase- (HRP-)
conjugated anti-rabbit from The Jackson Laboratory “Jax®,”
Sulzfeld, Germany (Cat. #: 111-035-144).
Other chemicals include isoflurane “Forene®” from
AbbVie Deutschland GmbH & Co. KG, Ludwigshafen,
Germany (Zul.-Nr.: 2594.00.00); paraformaldehyde from
Sigma-Aldrich Chemie GmbH (P6148-500G); D(+)-Saccha-
rose from Carl Roth GmbH+Co. KG, Karlsruhe, Germany
(Art.-Nr.: 4621.1); Precision Plus Protein™ Kaleidoscope™
from Bio-Rad, Mu¨nchen, Germany (Cat. #: 161-0375); bovine
serum albumin (BSA) from Sigma-Aldrich, Co., MO, USA
(PCode: 1001561418); 4′,6-diamidino-2-phenylindole (DAPI);
ethanol “99%” and β-mercaptoethanol from Carl Roth
GmbH+Co. KG, Karlsruhe, Germany; Novaminsulfon®
Lichtenstein “500mg metamizole sodium” drops from
Winthrop Arzneimittel GmbH, Mu¨lheim-Ka¨rlich, Germany
(Zul.-Nr. 6867259.00.00); 1,2,3,6-tetrahydro-1,3-dimethyl-N-
[4-(1-methylethyl)phenyl]-2,6-dioxo-7H-purine-7-acetamide
(HC-030031®) from Sigma-Aldrich Chemie GmbH (PCode:
H4415); Pierce™ BCA Protein Assay Kit from Thermo Sci-
entific; enhanced chemiluminescence “ECL” Kit from
Amersham Pharmacia Biotech, NJ, USA; and Nova-
minsulfon-ratiopharm® “1 g/2mL metamizole sodium am-
poules” from ratiopharm GmbH, Ulm, Germany.
Equipment used in this study were Axiovert 25 inverted
microscope (Carl Zeiss, Go¨ttingen, Germany); Touch Test®
Sensory Evaluators (North Coast Medical, Inc., CA, USA);
Trans-Blot® Turbo™ Transfer System and nitrocellulose
membranes (Bio-Rad, CA, USA); ChemiDoc™ MP Imaging
System (Bio-Rad); CryoStar™ NX70 (Thermo Fisher Sci-
entific™ Inc.); Mastercycler® Pro Thermal Cycler (Eppen-
dorf AG, Hamburg, Germany); TaqMan™ 7500 Real-Time
PCR System (Applied Biosystems, Thermo Scientific); UGO
BASILE Plantar Test 37,370 (Ugo Basile® SRL, Varese, Italy);
and Zeiss® LSM 510 laser scanning microscope (Carl Zeiss).
2.4. Behavioral Assay
2.4.1. Cold Allodynia. The acetone test was used to assess
cold allodynia by exposing the animals (n  6 for each
group) to cold stimuli and counting their responses as the
number of flicking or licking. Every single measurement
was performed in a duplicate, with a 5-minute interval
between each, and the average was calculated [34, 35]. The
test was performed in cancer-injected and sham animals
for baseline measurement. It was also performed at the 7th
day after subcutaneously injecting the selective TRPA1
antagonist HC-030031 (at 15, 30, 60, 90, and 120min).
HC-030031 was dissolved in DMSO and then diluted in
ethanol : water mixture (10 : 90 v/v) to give final concen-
trations of 25 and 50mg/kg.
2.4.2. Mechanical Hyperalgesia. The Von Frey test was
performed to measure hypersensitivity to mechanical
stimuli by using Touch Test Sensory Evaluators (North Coast
Medical, Inc.). The evaluators included filaments with log-
arithmic increments in force applied on the rats’ hind paws
(n 7 for each group). The test was applied for the assess-
ment of mechanical sensitivity in sham and cancer rats.
The 50% g threshold was calculated using the up-and-down
method with X positive- and O negative-responses
according to Dixon’s formula:
50% g threshold 
10 Xf+Kδ[ ]( )
10, 000
, (1)
where Xf  the value of the last filament used (in log unit),
K the tabular constant for OX series, and δ  the mean
interval (in log unit; here 0.229) [36, 37].
To calculate the interval (δ), we calibrated the filaments
by taking the mean of 10 measurements for each one. The
tabular values (K) were provided as constants according to
Dixon [38] and Chaplan et al. [37].
2.4.3. Thermal Hyperalgesia. The animal response to nox-
ious heat stimuli was assessed by the Hargreaves method
[39] using Ugo Basile Plantar Test. The withdrawal latency
was measured in sham and cancer-inoculated animals (n 8
for each group) as a mean of duplicate measurements (in
seconds).
2.5. Morphology and Light Microscope. The shape of the
ipsilateral hind paw in the cancer-injected rats was com-
pared to the ipsilateral hind paw of the sham-operated rats
and to the contralateral side of the same rat. After removal of
the SNs, they were further checked at different time points
for formation of malignant lumps and the gradual thick-
ening and weight gain.
The invasion process and the morphological changes
within the SNs were histologically examined by a light
microscope. Tissues of the SNs from each group of sham and
cancer animals were cut into sections (Section 2.7) and
stained by hematoxylin and eosin. We visualized longitu-
dinal sections of the SNs using an Axiovert 25 inverted
microscope assembled with a CCD camera (AxioCam HRc).
2.6. Gel Electrophoresis and Western Blotting. TRPA1 was
semiquantitatively assessed using Western blotting. The bi-
lateral lumbar DRGs, L3–5, were collected from each group of
animals and homogenized. DRG proteins were then extracted
and measured using a Pierce BCA Protein Assay kit. They
were added to a mixture of 2-mercaptoethanol and bromo-
phenol blue and then separated on sodium dodecyl sulphate
polyacrylamide gel (8%), using 7.5μg protein per lane. The
proteins were blotted on the nitrocellulose membrane using
Trans-Blot Turbo Transfer System.
The blots were immersed in BSA for 90min to block any
nonspecific binding. Then, they were incubated overnight
at 4°C with the anti-TRPA1 antibody (1 : 100) in BSA.
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We incubated the blots again for 120min at room temperature
with the secondary antibody. The secondary antibody used
was horseradish peroxidase- (HRP-) conjugated anti-rabbit
(1 : 40,000) in BSA. Then, the antigen-antibody complexes
were visualized using the ECL kit. Images were captured by
ChemiDoc MP Imaging System. To view the housekeeping
protein band [40], we used the monoclonal anti-β-actin–
peroxidase (1 : 25,000) in BSA. Fiji software was used to
adjust the brightness and the contrast of images and to
subtract the background and to invert the color [41]. The
regions of interest (ROIs) were then selected for all the bands
(n 11 for each group) for which the integrated densities
were measured. The integrated densities were then calcu-
lated as percentages to the corresponding control and
compared to each other.
2.7. Immunofluorescence Double-Staining. To quantify
TRPA1 and CGRP in DRGs, we used double-staining im-
munohistochemistry. Isoflurane was used to anaesthetize the
rats, which were then transcardially perfused with 100mL of
a pH-7.4 PBS and then with 500mL of 4% (w/v) para-
formaldehyde in PBS. Lumbar L3–5 DRGs were collected in
the same fixative and kept on the benchtop for 90min.Then,
they were washed with PBS and stored overnight at 4°C in
10% sucrose solution in PBS as a cryoprotectant. Next, they
were embedded in an optimal-cutting-temperature (OCT)
medium and stored at −20°C prior to cryostasis.
Tissues were cut into ultrathin sections ranging between
5 and 7 µmwith CryoStar NX70.The sections were mounted
onto gelatin-precoated slides and incubated overnight at
room temperature with the primary anti-TRPA1 and anti-
CGRP antibodies. Then, they were washed and incubated
again with the corresponding secondary antibodies (Alexa
Fluor 594 donkey anti-rabbit IgG and Alexa Fluor 488
donkey anti-mouse IgG, resp.). Nuclear DNA was labeled
with DAPI according to the Chazotte protocol [42]. A laser
scanning microscope, Zeiss LSM 510, was used to view the
slides and to capture the photos (n 10 for each group).
These photos were used to count positive immunoreactive
(+IR) cells relative to their total number (as percentage).
2.8. Measurement of mRNA (qRT-PCR). RNA was extracted
from L3–5 DRGs of animals (n 9 for each group) using an
RNeasy kit (Qiagen, Hilden, Germany). Specific forward and
reverse primers were used for cDNA synthesis. The quan-
tification step was performed, by TaqMan 7500 Real-Time
PCR System, using 18S ribosomal RNA as the reference
normalization housekeeping gene [43].
2.9. Statistical Data Analysis. SigmaPlot 12.5 (Systat Soft-
ware, Inc., CA, USA), GraphPad Prism (GraphPad Software,
Inc., CA, USA), and Microsoft Excel 2016 (Microsoft Corp.)
were used for doing statistics, graphs, and tabular data
description. Data were expressed as mean± standard error
of mean (SEM). Results were tested for potential outliers.
One-way analysis of variance (ANOVA) followed by Tukey’s
or Dunnett’s post hoc test was used to make pairwise or
versus control comparisons, respectively. The Kruskal–
Wallis test was used to analyze variances on ranks if the
normality test failed. Values of at least P< 0.05 were con-
sidered statistically significant.
3. Results
3.1. Induction of Neuropathic Pain. After inoculation of the
tumor cells, we assessed the macroscopic and microscopic
nerve characters and the pain behaviors. As expected, tumor
growth took place only in the cancer-inoculated and not in
the sham groups (Figure 1(a)). Moreover, the gradual
proliferation of the tumor was only noticed in the ipsilateral
and not in the contralateral hind paws (Figures 1(b)–1(e)).
Histology of the SNs was examined for evidence of
tumor growth, nerve degeneration, and infiltration of im-
mune cells. In sham animals, SN micrographs revealed
normal fascicles with the characteristic curvy appearance
and rod-like strands of nerve fibers. The nuclei of the
Schwann cells and the fibrocytes were shown with no clear
differentiation between them (Figure 2(a)).
In cancer-inoculated animals, the SNs were infiltrated by
mononuclear cells. In addition, the gradual growth of the
tumor from day 3 to day 21 was indicated by loss of integrity
(a) (b) (c) (d) (e)
Figure 1: Morphological changes after AT-1 cell injection. (a) Sciatic nerves (SNs) are exposed in cancer (upper) and sham (lower) animals
where the nerve thickness and the solid lump distinguish the cancerous one. (b) Signs of pain appear in the ipsilateral (right) and not in the
contralateral (left) paw of the Copenhagen rat. Figures (c–e) show the gradual growth of the tumorous (upper) nerves in the cancer-injected
animals at days 7 (c), 14 (d), and 21 (e). The nontumorous (lower) nerves are placed below for comparison.
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and degeneration of nerve fibers and the increasing number
of nuclei over time (Figures 2(b)–2(e)).
The neuropathy was induced by injecting AT-1 cancer
cells. Cold allodynia and mechanical and thermal hyper-
algesia were estimated from day zero, “the baseline,” to day
fourteen in ipsilateral sides of both sham-operated and
cancer-injected rats (Figure 3). The contralateral sides did
not show any degree of neuropathic pain.
Cold allodynia was measured as the number of re-
sponses in sham and cancer animals (n  6 for each group).
In the sham group, the cold allodynia did not change
during the observation period. In cancer animals, the
(a) (b)
(c) (d)
(e)
Figure 2: Light micrographs of the longitudinal sections of the sciatic nerve. (a) SNs of sham-operated animals show normal fascicles and
a wavy pattern of the intact fibers which characterize normal nerves. (b–e) SNs of cancer-injected animals (at days 3, 7, 14, and 21, resp.)
show a gradual invasion of cancer cells accompanied by a degradation of the nerve fibers. SNs are stained by hematoxylin and eosin (×20).
Scale bars 100μm.
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hypersensitivity did not change until day 5 and then sig-
nificantly increased at days 6 (18 ± 1.3), 8 (19± 1.4), 10 (18±
1.3), 12 (19 ± 1.3), and 14 (20 ± 1.7) as compared to (3.5 ±
0.93) for day zero (Figure 3(a)).
Mechanical pain measurements (n 7 for each group)
did not change in sham animals. In cancer animals, there
was no change from day 1 to day 5. However, a significant
increase in the degree of pain was observed from day 6 to day
14. The degree of pain was indicated by the decrease in
applied force. The 50% g threshold dropped to (5.6± 1.9) on
day 6 and then to (0.84± 0.12) during days 7 and 8 and
reached a lowest value of (0.40± 0.0) over days 9 to 14. All
values were compared to day zero (10± 0.32) (Figure 3(b)).
Hargreaves’ test was performed (n 8 for each group) for
sham and cancer animals (Figure 3(c)). In sham animals, there
was a decrease in the degree of nociception (i.e., an increased
tolerance time) at day 2 (20± 1.0) with (P< 0.05) as compared
to the control (16± 0.7). Then, it did not change till the end of
the observation period. In cancer rats, the sensitivity to thermal
stimuli decreased at day 2 (19± 0.86) with (P< 0.01), did not
change at day 4, and then increased at days 6 (5.7± 0.68), 8
(4.9± 0.29), 10 (4.5± 0.18), 12 (3.9± 0.23), and 14 (4.6± 0.26)
with (P< 0.0001) as compared to day zero (15 ± 0.77).
3.2. Upregulation of TRPA1 and CGRP in Afferent DRG
Neurons. Immunofluorescent images of DRG tissues were
double-stained to show TRPA1 and CGRP expression as
well as nuclei proliferation. The satellite cells in these images
characterize the morphology of the peripheral neuroglia.
Despite exhibiting similar upregulation, each had a different
expression pattern.
On one hand, TRPA1 expression, as indicated by +IR
cells, did not change till day 3. Then, it substantially in-
creased until it reached its peak at day 7 (P< 0.01) and stayed
significant until day 14 (P< 0.05). After day 14, it decreased
at the same rate until it returned to its normal level at day 21.
On the other hand, CGRP started with a slower rate of
expression. It reached its maximum at day 14 and stayed at
the same level till day 21 (P< 0.001). The nuclei stained with
DAPI followed an increasing proliferation pattern similar to
the CGRP one. It increased slowly from day 1 to day 7.Then,
it dramatically increased at days 14 and 21 (Figure 4).
The upregulation of TRPA1 and CGRP and the pro-
liferation of the nuclei as a response to the growing tumor
were confirmed by the relative counting of the +IR cells
(Figure 5). For TRPA1, the average of +IR cells was 42± 2.8
for the sham group, 55± 3.4 (P< 0.01) for the day 7 group,
and 53± 2.5 (P< 0.05) for the day 14 group (Figure 5(a)).
The average of CGRP +IR cells was 35± 2.2 for the sham
group, 52± 3.2 (P< 0.001) for the day 14 group, and 52± 3.3
(P< 0.001) for the day 21 group (Figure 5(b)). Nuclei
counting revealed a significant increase at days 7 (213± 17;
P< 0.05), 14 (225± 11;P< 0.01), and 21 (244± 12;P< 0.0001)
as compared to (168± 11) of the sham group (Figure 5(c)).
The combined image of these three stains showed
a coexpression of TRPA1 and CGRP on the same cells
(Figure S1 in the supplementary file). In contrast to the
sham group (9.3± 1.2), the coexpression increased at day 3
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Figure 3: Cold allodynia and mechanical and thermal hyper-
algesia. The number of responses to cold (n 6), mechanical
(n  7), and thermal (n  8) stimuli at the hind paw of the cancer
animals is measured. (a) Substantial increase of cold allodynia
from day 6 to day 14 (P< 0.0001) as indicated by an increased
number of responses. (b) Significant increase of mechanical
hyperalgesia from day 6 to day 14 (P< 0.0001) as indicated by
decreased applied forces. (c) Thermal hyperalgesia significantly
decreases at day 2 (P< 0.01) followed by an increase from day 6 to
day 14 (P< 0.0001). Time points are all compared with control
(day zero).
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Figure 4: Double immunofluorescent micrographs of DRG neurons for control and 3-, 7-, 14-, and 21-day groups (n 10). From left to
right: TRPA1 is red, CGRP is green, nuclei (DAPI) is blue, and the merged is a combined image of the three. The yellow color indicates the
coexpression of TRPA1 and CGRP on the same cells. Scale bars 50μm.
Pain Research and Management 7
(19± 1.9;P< 0.05) and becamemore significant at day 7 (38±
4.9; P< 0.0001). It then decreased at day 14 (28± 3.0;
P< 0.0001) and day 21 (23± 2.4; P< 0.01).
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Figure 5: Quantification of TRPA1 and CGRP immunoreactive cells in DRGs as compared to the sham group. (a) TRPA1 shows a higher
significance at day 7 (P< 0.01) and then a less at day 14 (P< 0.05). (b) CGRP shows a high significance at days 14 and 21 (P< 0.001).The numbers
of +IR cells is expressed as percentage of total cells. (c) DAPI-stained nuclei are increased at days 7 (P< 0.05), 14 (P< 0.01), and 21 (P< 0.0001).
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Figure 7: Quantification of TRPA1 mRNA in control and 3-, 7-,
14-, and 21-day groups (n 9). Results are calculated and nor-
malized to 18S rRNA as a preferred housekeeping gene.
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Figure 6: Immunoblots and quantitative densitometry of TRPA1.
The bands show TRPA1 (130 kDa) and the internal standard,
β-actin (42 kDa), blotted. The mean of the integrated density of
each group of samples (n 11) was measured and expressed as
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The blots showed a trend of TRPA1 expression similar to
that in the immunofluorescence images (see Figure S2 and
S3 in the supplementary file). They did not change at days
3 and 7 and then significantly increased at day 14 (154± 25;
P< 0.05) and reversed at day 21 (110± 8.34) as compared to
sham (100± 0.0) (Figure 6).
The real-time polymerase chain reaction results showed
the same pattern as immunohistochemistry images. The
expression values of TRPA1 mRNA increased at day 7 (3.6±
0.55; P< 0.0001) and then became lower at day 14 and were
restored at day 21 (Figure 7).
3.3. Transient Reversal of ColdAllodynia. To study the effect
of the TRPA1 selective antagonist HC-030031, we injected
the animals with two doses of HC-030031 (25 and
50mg/kg). The number of responses was measured at 15,
30, 60, 90, and 120 minutes and compared to the maxi-
mum of hypersensitivity reached previously at day 6
(Figure 3(a)).
For the 25mg/kg dose, the number of responses de-
creased to (13± 0.9; P< 0.05) at minute 15. The pain re-
lapsed quickly at minute 30, and the number of responses
increased again to (21 ± 1.0) and plateaued to the end of
measurement.
The 50mg/kg dose had a longer lifetime as the number of
responses significantly decreased to (7.0± 0.8; P< 0.0001) at
minute 15 and stayed significant till minute 30 (9.0± 0.5;
P< 0.0001). The pain relapsed again, and the number of
responses increased to (17± 1.0) at minute 60, which was
lower than that of the 25mg/kg dose at the same time point
(Figure 8).
4. Discussion
Most of the established cancer-induced pain models are bone
cancers. The pain behaviors in these models were reported at
three [44] or four [45, 46] weeks after injection time in mice
and around one week in rats [47]. To our knowledge, no
cancer-induced neuropathic pain models were designed by
direct inoculation of cancer cells within a peripheral nerve. In
the current study, we introduce a novel model of cancer-
induced neuropathy developed by direct injection of tumor
cells into the neuronal sheath of the sciatic nerve.
In a previous study, cancer cells were injected in the close
vicinity of the sciatic nerve in mice. Mechanical and thermal
hyperalgesia was reported at days 10 to 14. This hyperalgesia
was correlated with a mild degeneration of myelin at day
10 followed by a progressive degeneration until day 14 [6].
A similar model reported a significant mechanical hyper-
algesia at day 14 and day 17. In this study, sensation was lost
at day 21 [7].
In our model, tumor growth was morphologically ver-
ified by the constant increase in size and thickness of the
anaplastic tumor-1 (AT-1) cell-injected sciatic nerves and
the continuous formation of malignant lumps. The in-
vasiveness of the cells was minimal as compared to other
models, and hence, the duration of pain was longer [6, 7].
Microscopic examination confirmed infiltration of mono-
nuclear cells throughout the fascicular mass as well as
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Figure 8: Cancer-induced neuropathy and its reversal using the selective TRPA1 antagonist HC-030031: the neuropathic pain (as indicated
by cold allodynia) and its reversal in cancer animals injected with 50 and 25mg/kg and vehicle (n 6 for each group).TheHC-030031 dose of
25mg/kg restored the cold allodynic pain at 15 minutes (P< 0.05), while the 50mg/kg dose showed a high significance (P< 0.0001) at 15 and
30 minutes.
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degeneration of nerve fibers. Evidence of neuropathic pain
was shown by the progressive cold allodynia and mechanical
and thermal hyperalgesia as compared to sham-operated
animals.
Upon the development of such a local nonmetastasizing
malignancy, the afferent DRG sensory neurons showed
major changes on the molecular level. On one hand, the
overexpression of the transient receptor potential ankyrin 1
(TRPA1) in the DRG itself mediates molecular responses to
cancer development [19, 20] and transduces cold stimuli to
the nociceptor sensory neurons. We observed that this
overexpression is more significant upon inoculating tumor
cells within the neuronal sheath. On the other hand, the
number of calcitonin gene-related peptide (CGRP) +IR cells
shows a nearly similar attitude of increased expression in
response to the distant tumor growth.This is consistent with
previous studies confirming its release in cancer and other
chronic painful inflammatory conditions [48–50]. The
delayed release of CGRP (at day 14) than TRPA1 (at day 7)
suggests the dependence of CGRP production on TRPA1.
The concurrent expression of CGRP by TRPA1 +IR
neurons increases with continuous tumor growth and
neuronal damage.This implies a mutual synergistic function
of pain transduction. Although Barabas and colleagues re-
ported previously that the majority of TRPA1 +IR cells were
CGRP-negative [51], our results are in agreement with other
studies showing a high coexistence of TRPA1 and CGRP +IR
neurons on the same cells [52–54].
The fluorescence images of TRPA1 +IR cells comply with
a significant increase in TRPA1 mRNA at the same time
point as well as with a similar trend of quantitative protein
analysis using Western blot.
The noticeable increase in the number of nuclei in
fluorescence images is attributed to the recruitment of
immune cells to the nociceptive neurons. Most of the stained
nuclei appear to be nonneuronal because of the nonspecific
nature of the counterstain DAPI, which labels TRPA1 and
CGRP +IR cells as well as nonneuronal cells [55, 56].
With the continuous growth of cancer cells, pressure is
gradually exerted on the injection site of the sciatic nerve.
This pressure leads to an increase in the hypersensitivity to
cold stimuli as mentioned above. After the subcutaneous
injection of the selective TRPA1 antagonist HC-030031, the
cold allodynia is substantially suppressed, and the effect of
cancer-induced neuropathy is transiently reversed in a dose-
dependent manner. Transiently restoring the pain was
formerly achieved using the same antagonist in other types
of hypersensitivity [10–12, 19].
5. Conclusion
We successfully established a novel and a promising animal
model of perineural cancer cell invasion in Copenhagen rats.
This model was used for assessing cancer-induced neuro-
pathic pain (i.e., cold allodynia and mechanical and thermal
hyperalgesia) dependent on the degree of invasion. We also
investigated the molecular mechanisms underlying the
perineural invasion process and identified the role of the
pain recognition receptor TRPA1 and the pain transmitter
and vasodilator CGRP and highlighted their upregulation
and coexpression in the dorsal root ganglionic neurons.
Finally, we evaluated a therapeutic strategy for the relief of
this perineural cancer pain by blocking the TRPA1 channel.
Conflicts of Interest
The authors declare no conflicts of interest.
Authors’ Contributions
Ahmad Maqboul designed the study, performed the ex-
periments, analyzed the results, and wrote the manuscript.
Bakheet Elsadek contributed in the study design and writing
and reviewing the manuscript.
Acknowledgments
Thanks are due to Charite´–University of Medicine Berlin
for providing the research laboratories at the Department
of Anesthesiology and Operative Intensive Care Medicine.
Al-Azhar University is also acknowledged for supporting
this study. This work is financially supported by the
Egyptian Ministry of Higher Education (Cultural Affairs
and Missions Sector) for two years and the German
Foundation of Professor K. H. Rene´ Koczorek (Grant no.:
IA89838780) for one year.
Supplementary Materials
Figure S1: Quantification of TRPA1 and CGRP coexpression.
Figure S2: Anti-TRPA1 antibody (Santa Cruz, sc-66808),
130 kDa. Figure S3: Anti-β-actin antibody (Sigma, A3854),
42 kDa. (Supplementary Materials)
References
[1] C. Liebig, G. Ayala, J. A. Wilks, D. H. Berger, and D. Albo,
“Perineural invasion in cancer: a review of the literature,”
Cancer, vol. 115, no. 15, pp. 3379–3391, 2009.
[2] P. W. Mantyh, D. R. Clohisy, M. Koltzenburg, and S. P. Hunt,
“Molecular mechanisms of cancer pain,” Nature Reviews
Cancer, vol. 2, no. 3, pp. 201–209, 2002.
[3] H. Dai, R. Li, T. Wheeler et al., “Enhanced survival in peri-
neural invasion of pancreatic cancer: an in vitro approach,”
Human Pathology, vol. 38, no. 2, pp. 299–307, 2007.
[4] P. D. Wall, J. W. Scadding, and M. M. Tomkiewicz, “The
production and prevention of experimental anesthesia
dolorosa,” Pain, vol. 6, no. 2, pp. 175–182, 1979.
[5] G. J. Bennett and Y. K. Xie, “A peripheral mononeuropathy in
rat that produces disorders of pain sensation like those seen in
man,” Pain, vol. 33, no. 1, pp. 87–107, 1988.
[6] M. Shimoyama, K. Tanaka, F. Hasue, and N. Shimoyama, “A
mouse model of neuropathic cancer pain,” Pain, vol. 99, no. 1,
pp. 167–174, 2002.
[7] A. Hald, S. Nedergaard, R. R. Hansen, M. Ding, and
A. M. Heegaard, “Differential activation of spinal cord glial
cells in murine models of neuropathic and cancer pain,”
European Journal of Pain, vol. 13, no. 2, pp. 138–145, 2009.
[8] H. Wei, Y. Wei, F. Tian, T. Niu, and G. Yi, “Blocking
proteinase-activated receptor 2 alleviated neuropathic pain
10 Pain Research and Management
evoked by spinal cord injury,” Physiological Research/
Academia Scientiarum Bohemoslovaca, vol. 65, no. 1,
pp. 145–153, 2016.
[9] I. B. Philyppov, O. N. Paduraru, K. L. Gulak, R. Skryma,
N. Prevarskaya, and Y. M. Shuba, “TRPA1-dependent reg-
ulation of bladder detrusor smooth muscle contractility in
normal and type I diabetic rats,” Journal of Smooth Muscle
Research  Nihon Heikatsukin Gakkai kikanshi, vol. 52,
pp. 1–17, 2016.
[10] J. J. DeBerry, E. S. Schwartz, and B. M. Davis, “TRPA1
mediates bladder hyperalgesia in a mouse model of cystitis,”
Pain, vol. 155, no. 7, pp. 1280–1287, 2014.
[11] M. C. Dall’Acqua, I. J. Bonet, A. R. Zampronio, C. H. Tambeli,
C. A. Parada, and L. Fischer, “The contribution of transient
receptor potential ankyrin 1 (TRPA1) to the in vivo noci-
ceptive effects of prostaglandin E2,” Life Sciences, vol. 105,
no. 1-2, pp. 7–13, 2014.
[12] I. J. Bonet, L. Fischer, C. A. Parada, and C. H. Tambeli, “The
role of transient receptor potential A 1 (TRPA1) in the
development and maintenance of carrageenan-induced
hyperalgesia,” Neuropharmacology, vol. 65, pp. 206–212, 2013.
[13] S. Mergler, Y. Cheng, S. Skosyrski et al., “Altered calcium reg-
ulation by thermosensitive transient receptor potential channels
in etoposide-resistant WERI-Rb1 retinoblastoma cells,” Experi-
mental Eye Research, vol. 94, no. 1, pp. 157–173, 2012.
[14] I. Mukhopadhyay, P. Gomes, S. Aranake et al., “Expression of
functional TRPA1 receptor on human lung fibroblast and
epithelial cells,” Journal of Receptors and Signal Transduction,
vol. 31, no. 5, pp. 350–358, 2011.
[15] I. Kaji, Y. Yasuoka, S. Karaki, and A. Kuwahara, “Activation of
TRPA1 by luminal stimuli induces EP4-mediated anion se-
cretion in human and rat colon,” American Journal of
Physiology Gastrointestinal and Liver Physiology, vol. 302,
no. 7, pp. G690–G701, 2012.
[16] S. Uckert, J. E. Sonnenberg, K. Albrecht, M. A. Kuczyk, and
P. Hedlund, “Expression and distribution of the transient
receptor potential cationic channel ankyrin 1 (TRPA1) in the
human vagina,” International Journal of Impotence Research,
vol. 27, no. 1, pp. 16–19, 2015.
[17] M. H. Oh, S. Y. Oh, J. Lu et al., “TRPA1-dependent pruritus in
IL-13-induced chronic atopic dermatitis,” Journal of Immu-
nology, vol. 191, no. 11, pp. 5371–5382, 2013.
[18] K. J. Zappia, S. R. Garrison, O. Palygin et al., “Mechano-
sensory and ATP release deficits following keratin14-Cre-
mediated TRPA1 deletion despite absence of TRPA1 in
murine keratinocytes,” PLoS One, vol. 11, no. 3, p. e0151602,
2016.
[19] S. Ruparel, M. Bendele, A. Wallace, and D. Green, “Released
lipids regulate transient receptor potential channel (TRP)-
dependent oral cancer pain,” Molecular Pain, vol. 11, p. 30,
2015.
[20] Y. Ye, D. Dang, J. Zhang et al., “Nerve growth factor links oral
cancer progression, pain, and cachexia,” Molecular Cancer
Therapeutics, vol. 10, no. 9, pp. 1667–1676, 2011.
[21] S. D. Brain, T. J. Williams, J. R. Tippins, H. R. Morris, and
I. MacIntyre, “Calcitonin gene-related peptide is a potent
vasodilator,” Nature, vol. 313, no. 5997, pp. 54–56, 1985.
[22] D. L. Hay, C. S. Walker, and D. R. Poyner, “Adrenomedullin
and calcitonin gene-related peptide receptors in endocrine-
related cancers: opportunities and challenges,” Endocrine
Related Cancer, vol. 18, no. 1, pp. C1–C14, 2011.
[23] R. R. Hansen, V. Vacca, T. Pitcher, A. K. Clark, and
M. Malcangio, “Role of extracellular calcitonin gene-related
peptide in spinal cord mechanisms of cancer-induced bone
pain,” Pain, vol. 157, no. 3, pp. 666–676, 2016.
[24] W. S. Schou, S. Ashina, F. M. Amin, P. J. Goadsby, and
M. Ashina, “Calcitonin gene-related peptide and pain: a sys-
tematic review,” The Journal of Headache and Pain, vol. 18,
no. 1, p. 34, 2017.
[25] S. M.Mueller-Tribbensee, M. Karna, M. Khalil, M. F. Neurath,
P. W. Reeh, and M. A. Engel, “Differential contribution of
TRPA1, TRPV4 and TRPM8 to colonic nociception in mice,”
PLoS One, vol. 10, no. 7, p. e0128242, 2015.
[26] B. X. Huang, W. L. Cao, X. Huang et al., “Expressions of
transient receptor potential A1 and related inflammatory
factors in the rat model of prostatic inflammation,” Zhonghua
Nan Ke Xue  National Journal of Andrology, vol. 21, no. 1,
pp. 23–30, 2015.
[27] V. Meseguer, Y. A. Alpizar, E. Luis et al., “TRPA1 channels
mediate acute neurogenic inflammation and pain produced
by bacterial endotoxins,” Nature Communications, vol. 5,
p. 3125, 2014.
[28] M. Festing and J. Staats, “Standardized nomenclature for
inbred strains of rats: fourth listing,” Transplantation, vol. 16,
no. 3, pp. 221–245, 1973.
[29] J. T. Isaacs, W. B. Isaacs, W. F. Feitz, and J. Scheres, “Estab-
lishment and characterization of seven Dunning rat prostatic
cancer cell lines and their use in developing methods for
predicting metastatic abilities of prostatic cancers,” Prostate,
vol. 9, no. 3, pp. 261–281, 1986.
[30] F. D. Bullock and M. R. Curtis, “Spontaneous tumors of
the rat,” Journal of Cancer Research, vol. 14, no. 1, pp. 1–115,
1930.
[31] W. F. Dunning and M. R. Curtis, “The respective roles of
longevity and genetic specificity in the occurrence of spon-
taneous tumors in the hybrids between two inbred lines of
rats,” Cancer Research, vol. 6, pp. 61–81, 1946.
[32] W. F. Dunning, “Prostate cancer in the rat,” National Cancer
Institute Monograph, vol. 12, pp. 351–369, 1963.
[33] M. F. W. Festing, “Chapter 3 - Inbred strains,” in The Lab-
oratory Rat, H. J. Baker, J. R. Lindsey, and S. H. Weisbroth,
Eds., pp. 55–72, Academic Press, 1979.
[34] H. Xing, M. Chen, J. Ling, W. Tan, and J. G. Gu, “TRPM8
mechanism of cold allodynia after chronic nerve injury,”
Journal of Neuroscience, vol. 27, no. 50, pp. 13680–13690, 2007.
[35] L. Bardin, N. Malfetes, A. Newman-Tancredi, and
R. Depoortere, “Chronic restraint stress induces mechanical
and cold allodynia, and enhances inflammatory pain in rat:
relevance to human stress-associated painful pathologies,”
Behavioural Brain Research, vol. 205, no. 2, pp. 360–366, 2009.
[36] W. T. Dixon, “The up-and-down method for small samples,”
Journal of the American Statistical Association, vol. 60, no. 312,
pp. 967–978, 1965.
[37] S. R. Chaplan, F. W. Bach, J. W. Pogrel, J. M. Chung, and
T. L. Yaksh, “Quantitative assessment of tactile allodynia in
the rat paw,” Journal of Neuroscience Methods, vol. 53, no. 1,
pp. 55–63, 1994.
[38] W. J. Dixon, “Efficient analysis of experimental observations,”
Annual Review of Pharmacology and Toxicology, vol. 20, no. 1,
pp. 441–462, 1980.
[39] K. Hargreaves, R. Dubner, F. Brown, C. Flores, and J. Joris, “A
new and sensitive method for measuring thermal nociception
in cutaneous hyperalgesia,” Pain, vol. 32, no. 1, pp. 77–88,
1988.
[40] H. Towbin, T. Staehelin, and J. Gordon, “Electrophoretic
transfer of proteins from polyacrylamide gels to nitrocellulose
Pain Research and Management 11
sheets: procedure and some applications. 1979,” Biotechnology,
vol. 24, pp. 145–149, 1992.
[41] J. Schindelin, I. Arganda-Carreras, E. Frise et al., “Fiji: an
open-source platform for biological-image analysis,” Nature
Methods, vol. 9, no. 7, pp. 676–682, 2012.
[42] B. Chazotte, “Labeling nuclear DNA using DAPI,”Cold Spring
Harbor Protocols, vol. 2011, no. 1, p. pdb prot5556, 2011.
[43] T. D. Schmittgen and B. A. Zakrajsek, “Effect of experimental
treatment on housekeeping gene expression: validation by
real-time, quantitative RT-PCR,” Journal of Biochemical and
Biophysical Methods, vol. 46, no. 1-2, pp. 69–81, 2000.
[44] P. Honore, S. D. Rogers, M. J. Schwei et al., “Murine models of
inflammatory, neuropathic and cancer pain each generates
a unique set of neurochemical changes in the spinal cord and
sensory neurons,” Neuroscience, vol. 98, no. 3, pp. 585–598,
2000.
[45] A. P. Bloom, J. M. Jimenez-Andrade, R. N. Taylor et al.,
“Breast cancer-induced bone remodeling, skeletal pain, and
sprouting of sensory nerve fibers,” Journal of Pain, vol. 12,
no. 6, pp. 698–711, 2011.
[46] S. P. Alexander, K. Mackie, and R. A. Ross, “Themed issue:
cannabinoids,” British Journal of Pharmacology, vol. 160,
no. 3, pp. 421–422, 2010.
[47] T. Donovan-Rodriguez, A. H. Dickenson, and C. E. Urch,
“Superficial dorsal horn neuronal responses and the
emergence of behavioural hyperalgesia in a rat model of
cancer-induced bone pain,” Neuroscience Letters, vol. 360,
no. 1-2, pp. 29–32, 2004.
[48] P. Peng, Q. Xi, S. Xia et al., “Pregabalin attenuates docetaxel-
induced neuropathy in rats,” Journal of Huazhong University
of Science and Technology Medical Sciences, vol. 32, no. 4,
pp. 586–590, 2012.
[49] G. Calcott, J. P. White, and I. Nagy, “Xenon fails to inhibit
capsaicin-evoked CGRP release by nociceptors in culture,”
Neuroscience Letters, vol. 499, no. 2, pp. 124–126, 2011.
[50] N. G. Gracias, T. R. Cummins, M. R. Kelley, D. P. Basile,
T. Iqbal, and M. R. Vasko, “Vasodilatation in the rat dorsal
hindpaw induced by activation of sensory neurons is reduced
by paclitaxel,” Neurotoxicology, vol. 32, no. 1, pp. 140–149,
2011.
[51] M. E. Barabas, E. A. Kossyreva, and C. L. Stucky, “TRPA1 is
functionally expressed primarily by IB4-binding, non-
peptidergic mouse and rat sensory neurons,” PLoS One,
vol. 7, no. 10, p. e47988, 2012.
[52] T. Kondo, T. Oshima, K. Obata et al., “Role of transient
receptor potential A1 in gastric nociception,”Digestion, vol. 82,
no. 3, pp. 150–155, 2010.
[53] F. Cattaruzza, I. Spreadbury, M. Miranda-Morales,
E. F. Grady, S. Vanner, and N. W. Bunnett, “Transient re-
ceptor potential ankyrin-1 has a major role in mediating
visceral pain in mice,” American Journal of Physiology Gas-
trointestinal and Liver Physiology, vol. 298, no. 1, pp. G81–G91,
2010.
[54] T. Kondo, K. Obata, K. Miyoshi et al., “Transient receptor
potential A1 mediates gastric distention-induced visceral pain
in rats,” Gut, vol. 58, no. 10, pp. 1342–1352, 2009.
[55] D. J. Miller, P. Balaram, N. A. Young, and J. H. Kaas, “Three
counting methods agree on cell and neuron number in
chimpanzee primary visual cortex,” Frontiers in Neuroanat-
omy, vol. 8, p. 36, 2014.
[56] R. J. Mullen, C. R. Buck, and A. M. Smith, “NeuN, a neuronal
specific nuclear protein in vertebrates,” Development, vol. 116,
no. 1, pp. 201–211, 1992.
12 Pain Research and Management
